Comment on: TODAY Study Group. Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY. Diabetes Care 2013;36:1749–1757
Abstract
We read with great interest the TODAY study articles on adolescent diabetes and commend the editors of Diabetes Care for “sounding the alarm” about the impending adolescent diabetes epidemic in the June issue. Ten years ago, Narayan et al. (1) modeled a scenario where young people diagnosed with type 2 diabetes could expect to lose >15 years of relative life expectancy and >25 years of quality-adjusted life years. The TODAY study investigators, by quantifying micro- and macrovascular risk characteristics in young people with …
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.